SPY411.45-1.41 -0.34%
DIA337.53+0.74 0.22%
IXIC13,857.84-138.26 -0.99%

BRIEF-Merck KGaA Reports Topline Data For Bintrafusp Alfa

· 03/16/2021 03:03
BRIEF-Merck KGaA Reports Topline Data For Bintrafusp Alfa

- Merck KGaA MRCG.DE:

  • MERCK KGAA, DARMSTADT, GERMANY, REPORTS TOPLINE DATA FOR BINTRAFUSP ALFA AS SECOND-LINE MONOTHERAPY TREATMENT IN BILIARY TRACT CANCER

  • IN STUDY OF 159 PATIENTS, BINTRAFUSP ALFA DEMONSTRATED SINGLE-AGENT EFFICACY AND DURABILITY WITH A MANAGEABLE SAFETY PROFILE AFTER MORE THAN NINE MONTHS OF FOLLOW-UP, WITH AN INDEPENDENT REVIEW COMMITTEE (IRC)-ADJUDICATED OBJECTIVE RESPONSE RATE (ORR) OF 10.1% (95% CI: 5.9% TO 15.8%) PER RECIST 1.1.

Source text for Eikon: ID:nPn19hZhxa

Further company coverage: MRCG.DE


(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))